You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

March 23, 2015

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

Corticosteroids recommended for severe pneumonia

Because the use of corticosteroids in patients with severe community-acquired pneumonia is controversial, researchers in Spain set out to determine the benefits versus the pitfalls of using the adjunctive therapy. » Read more

New dose of Viibryd approved to treat major depressive disorder in adults

FDA has approved a new dose of vilazodone (Viibryd, Actavis) for the treatment of major depressive disorder (MDD) in adults.
» Details

Continuing Education

2015 Updates on the national guidelines for diabetes management and related disorders

Last month and this month pharmacists will be able to learn about the latest developments in diabetes treatment and management. Pharmacists can earn up to 4 hours of CPE credit with two monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics. The goal of this month’s activity is to discuss the recent updates of national U.S. guidelines for diabetes management, including hypertension and cholesterol management in patients with diabetes, in order to empower pharmacists in clinical decision-making.

Read/print the article: Click here

Take the test: Click here to log in with the Session Code 15DT16-TAJ88.


Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

Study: Genetic variants determine whether aspirin/NSAIDS will reduce colorectal cancer risk

Regular use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) appears to reduce the risk of colorectal cancer in most individuals, but a few individuals with rare genetic variants do not share this benefit, according to a study published in the March 17 issue of JAMA. » Study results

POLL:

A new class of biologics in the PCSK9 Inhibitors likely will be approved for treating high cholesterol. How are you preparing?

 

RELATED ARTICLES

Class action suit targets asthma drug

First atypical antipsychotic approved for pediatric patients with bipolar I disorder in 5 years

RESOURCES

Latest Clinical News

Powered by Modern Medicine Advanstar Medical Communications Group